FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
-
-
-
-
-
-
-
Telix to Host R&D Day in New York City on September 22, 2026
-
-
-
-
-
-
-
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
-
-
-
-
-
-
-
Telix presents prostate cancer trial data showing acceptable safety
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
-
-
-
-
-
-
-
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
-
-
-
-
-
-
-
Telix reports positive China trial data for prostate cancer imaging agent
-
335,957 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


